We are live on
!
Find out more
PA
PharVision Advisers Portfolio holdings
AUM
$9.86M
1-Year Est. Return
9.93%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+9.93%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$198M
AUM Growth
+$19.8M
(+11%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
11.78%
Top 10 Holdings %
Top 10 Hldgs %
3.45%
Holding
1,063
New
409
Increased
141
Reduced
117
Closed
396
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek US
DK
|
+$871K |
| 2 |
Broadcom
AVGO
|
+$691K |
| 3 |
Agilent Technologies
A
|
+$650K |
| 4 |
Telos
TLS
|
+$640K |
| 5 |
Pagaya Technologies
PGY
|
+$627K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Technologies
ARRY
|
+$730K |
| 2 |
Vertiv
VRT
|
+$639K |
| 3 |
Zevra Therapeutics
ZVRA
|
+$635K |
| 4 |
BOW
Bowhead Specialty Holdings
BOW
|
+$608K |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$581K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.19% |
| 2 | Industrials | 15.13% |
| 3 | Financials | 12.4% |
| 4 | Consumer Discretionary | 11.79% |
| 5 | Healthcare | 11.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1051
Hafnia
HAFN
$3.73B
| – | – |
-21,155
| Closed | -$127K |
|
1052
Loar Holdings
LOAR
$6.72B
| – | – |
-2,727
| Closed | -$218K |
|
|
MRX
1053
Marex Group Limited Ordinary Shares
MRX
$4.65B
| – | – |
-9,225
| Closed | -$310K |
|
|
BOW
1054
Bowhead Specialty Holdings
BOW
$1.02B
| – | – |
-22,482
| Closed | -$608K |
|
|
ALMS
1055
Alumis Inc
ALMS
$3.45B
| – | – |
-20,693
| Closed | -$82.6K |
|
|
DGNX
1056
Diginex Ltd
DGNX
$43.9M
| – | – |
-2,274
| Closed | -$262K |
|
|
LZMH
1057
LZ Technology Holdings
LZMH
$11.6M
| – | – |
-879
| Closed | -$57.8K |
|
|
RHLD
1058
Resolute Holdings Management
RHLD
$1.06B
| – | – |
-2,845
| Closed | -$205K |
|
|
EPSM
1059
Epsium Enterprise
EPSM
$18.5M
| – | – |
-11,030
| Closed | -$118K |
|
|
BCPC
1060
Balchem Corp
BCPC
$5.29B
| – | – |
-1,994
| Closed | -$299K |
|
|
ARAI
1061
Arrive AI Inc
ARAI
$14.9M
| – | – |
-16,511
| Closed | -$60.1K |
|
|
JBS
1062
JBS N.V.
JBS
$44.6B
| – | – |
-13,601
| Closed | -$203K |
|
|
JCAP
1063
Jefferson Capital
JCAP
$1.26B
| – | – |
-13,321
| Closed | -$230K |
|
Similar funds
BS
RG
MP
CCM
DFA
CCP
FRT
VH
PharVision Advisers's Q4 2025 Portfolio in Review
As of Q4 2025, PharVision Advisers held 1,063 positions worth $198M, up 11% from $178M the previous quarter. Its ten largest holdings account for 3.5% of the portfolio.
PharVision Advisers deployed $23.3M of net new capital in Q4 2025, opening 409 new positions and adding to 141 existing holdings. Its largest new stake was Delek US: 24,407 shares worth $724K.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Wayfair, an estimated $510K trimmed.
- PharVision Advisers's largest Q4 2025 buy was Delek US: 24,407 shares worth $724K.
- PharVision Advisers added most to NIO in Q4 2025, an estimated $557K increase.
- PharVision Advisers's biggest Q4 2025 reduction was Wayfair, cutting an estimated $510K.
- PharVision Advisers fully exited Array Technologies in Q4 2025, selling an estimated $730K.
- PharVision Advisers's ten largest holdings make up 3.5% of its $198M portfolio in Q4 2025.
- PharVision Advisers opened 409 new positions and closed 396 in Q4 2025.
- PharVision Advisers's portfolio value rose 11% quarter-over-quarter to $198M.
Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.